Author

S. Jabar

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Cancer Biology· 1 Immunology· 1 Pathology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:differential expression· 2 Approach:experimental assay· 2 Approach:statistical model· 2 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Assay:protein sequence· 1

Frequent Co-Authors

A. Marchetto· 2 shared A. Ranft· 2 shared B. R. Kiefel· 2 shared F. Cidre-Aranaz· 2 shared F. S. Wehweck· 2 shared J. Li· 2 shared J. Musa· 2 shared L. Romero-Perez· 2 shared

Activity by Year

2018-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Marchetto

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Structural principles of peptide-centric Chimeric Antigen Receptor recognition guide therapeutic expansion

Y. Sun, T. J. Florio, S. Gupta, M. C. Young, Q. F. Marshall, S. E. Garfinkle, G. F. Papadaki, H. V. Truong, E. Mycek, P. Li, A. Farrel, N. L. Church, S. Jabar, M. D. Beasley, B. R. Kiefel, , N. G. Sgourakis

This paper determines the structure of a peptide-centric Chimeric Antigen Receptor (PC-CAR) complex and identifies structural principles for antigen recognition across multiple HLA allotypes.

bioRxiv · May 24, 2023Biochemistry

Translational evidence for RRM2 as a prognostic biomarker and therapeutic target in Ewing sarcoma

S. Ohmura, A. Marchetto, M. F. Orth, J. Li, S. Jabar, A. Ranft, E. Vinca, K. Ceranski, M. J. Carreno-Gonzalez, L. Romero-Perez, F. S. Wehweck, J. Musa, F. Bestvater, M. M. L. Knott, T. L. B. Hoelting, , T. G. P. Grunewald

This study identifies RRM2 as a prognostic biomarker and therapeutic target in Ewing sarcoma, showing its overexpression correlates with poor survival and that its inhibition reduces tumor growth and overcomes chemoresistance.

bioRxiv · Mar 4, 2021Cancer Biology

Antibodies that potently inhibit or enhance SARS-CoV-2 spike protein-ACE2 interaction isolated from synthetic single-chain antibody libraries

M. D. Beasley, S. Aracic, F. M. Gracey, R. Kannan, A. Masarati, S. R. Premaratne, M. Udawela, R. E. Wood, S. Jabar, N. Church, T.-K. Le, D. Makris, B. K. McColl, B. R. Kiefel

bioRxiv · Jul 27, 2020 · PreprintImmunology

SOX2 expression identifies Ewing sarcoma patients with high risk for tumor relapse and poor survival

G. Sannino, A. Marchetto, A. Ranft, S. Jabar, C. Zacherl, R. Alba-Rubio, S. Stein, F. S. Wehweck, M. M. Kiran, T. L. B. Hoelting, J. Musa, L. Romero-Perez, F. Cidre-Aranaz, M. M. L. Knott, J. Li, , T. G. P. Grunewald

bioRxiv · Dec 17, 2018Pathology